The Association of the British Pharmaceutical Association (ABPI) has responded to the recent report of the National Audit Office (NAO) with regard to this investigation into the Cancer Drugs Fund.
In its final report on the subject, the NAO concluded that there are major problems with regard to the fund in the immediate future.
It was asserted by the NAO that unless significant measures were taken to improve the funding of the Cancer Drugs Fund, numerous medicines would need to be removed from... Readmore
A new tablet intended to prevent HIV infections in individuals at particularly high risk appears to provide a large success rate.
Two new studies that assess the efficacy of Truvada, manufactured by Gilead, conclude that the medicine is positively impacting on the development of HIV.
The first of the two studies was conducted in the San Francisco area, and researchers found that 657 people who consumed Truvada on a daily basis did not contract HIV.
Truvada’s efficacy was also tested in another... Readmore
A new drug that has a significant influence on the likelihood of being infected with HIV is being strongly promoted by experts.
Pre-exposure prophylaxis (PrEP) is being heralded as a massive breakthrough in treating HIV and AIDS, after researchers in a UK-based study found that it decreased infections by 86 per cent among gay men at high risk.
Scientists involved in the study opined that the NHS simply “cannot afford to ignore” this HIV treatment.
Having carried out a trial at 13 sexual health... Readmore
The ABPI and the Department of Health have announced their intention to underwrite the growth in the medicines bill for the second quarter of 2015.
This initiative will be taken under the Pharmaceutical Price Regulation Scheme (PPRS) that was agreed last year.
The PPRS is a purely voluntary agreement between the two parties involved, although the existing understanding between the Department of Health and ABPI will run until the end of 2018, having come into effect on 1st January, 2014.
The Cancer Drugs Fund in England has announced that it is to effectively eliminate a raft of medicines that have previously been utilised in cancer treatment.
This will effect 16 medicines that have previously been used in no less than 23 cancer treatments.
With this latest decision, the Cancer Drugs Fund has taken the radical action of effectively more than halving the number of treatments it covers.
The fund had suffered from repeated budgetary difficulties, and this has been the primary motivation... Readmore
According to a newly released report from Moody’s, the industrial outlook for the global pharmaceutical industry looks to be extremely healthy.
Although the pharmaceutical industry will experience pricing pressure over the next 12 to 18 months, the success of new products will more than offset this issue.
Key European pharmaceutical manufacturers such as AstraZeneca are predicted to play a major role in the industry going forward.
Moody’s also suggests that oncology will be the largest growth... Readmore
Considering the sensitivity of data protection and related topics in the existing client, a new survey provides a damning indictment of the pharmaceutical sector.
According to the Crown Records Management / Censuswide Survey, 60 per cent of pharmaceutical companies have lost important data, and nearly one-in-four have been successfully breached by hackers.
The survey which quizzed IT decision-makers at UK companies which boast more than 200 employees will of serious concern, particularly owing... Readmore
The Medicines and Healthcare products Regulatory Agency (MHRA) is asking people using steel cannula infusion sets to check them before and after use as the regulator believes there is a small risk of its needle breaking.
The needles are part of infusion sets, manufactured by Unomedical, which are used in hospitals and by people at home for the infusion of medicine through an external pump. They are primarily used by patients with diabetes, Parkinson’s disease and for the treatment of chronic... Readmore
The NHS Employers organisation has reached agreement on a number of changes to the Community Pharmacy Contractual Framework (CPCF) in return for a funding package of £2.8bn for 2015/16.
The agreed changes to the CPCF follow complex but constructive negotiations between all the interested parties (NHS Employers, the Pharmaceutical Services Negotiating Committee (PSNC) and NHS England).
NHS Employers and PSNC have agreed to a new advanced service for influenza vaccinations. Adult patients, aged... Readmore
Collaborative approaches to supporting innovation and to facilitating clinical development and timely access to new treatments and vaccines for patients were unveiled in a new report this week.
The report, from the UK BioIndustry Association (BIA) and Medicines and Healthcare products Regulatory Agency (MHRA) follows their annual conference - ‘Pathway of Innovation from Research to Patients’ – in London last month.
The event was attended by over 140 delegates from patients’ groups,... Readmore
New guidance which tackles the issues facing battery design, development and use in the medical and healthcare sector has been made available this week by battery manufacturer Accutronics.
It is intended to help Original Equipment Manufacturers (OEMs) better understand the possibilities and limitations of rechargeable battery technology in designing products for the sector.
The Accutronics guidance is free to download and aims to inform its readers on areas of recent battery design interest.... Readmore